Skip to main content
Terug
BIIB logo

Biogen Inc.

Datakwaliteit: 100%
BIIB
NASDAQ Healthcare Drug Manufacturers - General
€ 183,64
▲ € 2,18 (1,20%)
Marktkapitalisatie: 26,95B
Dagbereik
€ 183,02 € 185,00
52-Weeksbereik
€ 110,04 € 202,41
Volume
895.806
50D / 200D Gem.
€ 184,31 / € 156,87
Vorige Slotkoers
€ 181,46

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E 20,8 0,4
P/B 1,5 2,9
ROE % 7,4 3,7
Net Margin % 13,2 3,8
Rev Growth 5Y % -2,8 10,0
D/E 0,4 0,2

Belangrijkste Punten

Revenue declined -2,78% annually over 5 years
Earnings declined -20,76% over the past year
Debt/Equity of 0,38 — conservative balance sheet
Generating 2,05B in free cash flow
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 4,17%
Cash machine — converts 158,56% of earnings into free cash flow

Groei

Revenue Growth (5Y)
-2,78%
Revenue (1Y)1,39%
Earnings (1Y)-20,76%
FCF Growth (3Y)28,82%

Kwaliteit

Return on Equity
7,40%
ROIC5,59%
Net Margin13,18%
Op. Margin19,14%

Veiligheid

Debt / Equity
0,38
Current Ratio2,68
Interest Coverage7,63

Waardering

P/E Ratio
20,84
P/B Ratio1,48
EV/EBITDA16,45
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 1,39% Revenue Growth (3Y) -0,13%
Earnings Growth (1Y) -20,76% Earnings Growth (3Y) 5,54%
Revenue Growth (5Y) -2,78% Earnings Growth (5Y) -4,52%
Profitability
Revenue (TTM) 9,81B Net Income (TTM) 1,29B
ROE 7,40% ROA 4,39%
Gross Margin 70,47% Operating Margin 19,14%
Net Margin 13,18% Free Cash Flow (TTM) 2,05B
ROIC 5,59% FCF Growth (3Y) 28,82%
Safety
Debt / Equity 0,38 Current Ratio 2,68
Interest Coverage 7,63 Dividend Yield 0,00%
Valuation
P/E Ratio 20,84 P/B Ratio 1,48
P/S Ratio 2,75 PEG Ratio -0,95
EV/EBITDA 16,45 Dividend Yield 0,00%
Market Cap 26,95B Enterprise Value 30,89B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 9,81B 9,68B 9,84B 10,17B 10,98B
Net Income 1,29B 1,63B 1,16B 3,05B 1,56B
EPS (Diluted) 8,83 11,19 7,97 20,87 10,40
Gross Profit 6,91B 7,37B 7,30B 7,90B 8,87B
Operating Income 1,88B 2,49B 2,10B 2,89B 2,79B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 29,44B 28,05B 26,84B 24,55B 23,88B
Total Liabilities 11,18B 11,33B 12,05B 11,17B 12,92B
Shareholders' Equity 18,26B 16,72B 14,80B 13,40B 10,90B
Total Debt 6,95B 6,63B 7,34B 6,61B 7,60B
Cash & Equivalents 3,01B 2,38B 1,05B 3,42B 2,26B
Current Assets 8,97B 7,46B 6,86B 9,79B 7,86B
Current Liabilities 3,35B 5,53B 3,43B 3,27B 4,30B